Ninety-five patients. That is the entire enrollment for what Phathom Pharmaceuticals describes as the first large, placebo-controlled clinical trial of an acid suppression treatment in eosinophilic esophagitis, and the company filled those slots faster than its own timeline projected. The completion of enrollment in the pHalcon-EoE-201 study sets up topline data from the 12-week double-blind treatment phase by Q4 2026, which means Phathom could be sitting on a pivotal read before the end of this calendar year.
The design is straightforward: adults with endoscopically confirmed EoE and dysphagia, randomized 1:1 to vonoprazan 20 mg once daily or placebo for 12 weeks, with an open-label 12-week extension for completers. What makes the trial strategically consequential is the treatment class being tested. PPIs have served as a de facto first-line for EoE management for years despite carrying no FDA approval for the indication. Vonoprazan is a potassium-competitive acid blocker with more durable acid suppression than conventional PPIs, and Phathom is betting that a randomized, controlled dataset will establish something the PPI era never produced: actual clinical evidence for acid suppression in EoE. The estimated U.S. prevalence of roughly 472,000 cases, up fivefold since 2009, gives the commercial rationale real weight.
The competitive picture is not empty. Dupilumab earned FDA approval for EoE in adults and adolescents in May 2022 and subsequently expanded to pediatric patients as young as one year old in early 2024. That is a biologic, a subcutaneous injection, and a different mechanism entirely. Vonoprazan, if it works, would offer an oral, non-steroidal, non-biologic path, sitting in a mechanistic space that has no controlled evidence behind it yet. Phathom has already disclosed that positive Phase 2 data would prompt FDA discussions on a broader development program, including pediatric evaluation that could extend regulatory exclusivity.
The single number to track from here is the histologic responder rate at week 12. EoE trials typically define response as fewer than 15 eosinophils per high-power field on biopsy, and that threshold will determine whether vonoprazan cleared a bar meaningful enough to justify the Phase 3 investment Phathom is telegraphing.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
